382: Biotech's year in review
Episode
34 min
Read time
2 min
Topics
Productivity, Health & Wellness, Investing
AI-Generated Summary
Key Takeaways
- ✓Biotech Market Recovery: Clinical stage biotech companies surged 62% year-to-date, with the XBI index beating the S&P 500 by 200 basis points. The sector jumped 180% from April lows through December, driven by merger and acquisition momentum, positive clinical data, and perceived reduction in regulatory risks under the Trump administration's second term.
- ✓Direct-to-Consumer Drug Programs: Eli Lilly and Novo Nordisk's direct-to-consumer GLP-1 programs paradoxically reduce access by enabling employers to drop insurance coverage. HCA Healthcare, the largest US hospital system, eliminated Zepbound and Wegovy coverage for 2026, directing employees to manufacturer programs where costs increased from $100 to $449 monthly for some patients.
- ✓IPO Market Outlook: Biotech IPOs will increase significantly in 2026 after two barren years, but quality concerns persist as the entire ecosystem incentivizes public offerings regardless of company readiness. Historically, 60-75% of biotech IPOs underperform within two years, making careful stock selection critical for investors navigating the reopened market.
- ✓Obesity Drug Valuations: Obesity-focused biotech companies face pricing to perfection risk, where any clinical data falling short of beating Eli Lilly's tirzepatide triggers massive selloffs. Viking Therapeutics lost 40% market value in one day despite promising results, while Lilly dropped $60-70 billion on imperfect oral drug data, demonstrating extreme investor expectations.
- ✓Venture Capital Shift: Biotech's share of US venture capital dropped below 10% to approximately 7% for the first time in decades, down from 12-14% historically. Tech sector AI investments exploded the denominator while biotech stabilized at $5-6 billion quarterly. This creates overcapitalization risk for AI-native biotech companies backed by inexperienced investors making inflated valuation assumptions.
What It Covers
The Readout Loud reviews biotech's 2025 performance with venture capitalist Bruce Booth, covering market recovery data, CEO performance rankings, GLP-1 drug pricing dynamics, FDA stability concerns, and venture capital trends. Clinical stage biotechs gained 62% year-to-date while zombie biotech numbers declined significantly.
Key Questions Answered
- •Biotech Market Recovery: Clinical stage biotech companies surged 62% year-to-date, with the XBI index beating the S&P 500 by 200 basis points. The sector jumped 180% from April lows through December, driven by merger and acquisition momentum, positive clinical data, and perceived reduction in regulatory risks under the Trump administration's second term.
- •Direct-to-Consumer Drug Programs: Eli Lilly and Novo Nordisk's direct-to-consumer GLP-1 programs paradoxically reduce access by enabling employers to drop insurance coverage. HCA Healthcare, the largest US hospital system, eliminated Zepbound and Wegovy coverage for 2026, directing employees to manufacturer programs where costs increased from $100 to $449 monthly for some patients.
- •IPO Market Outlook: Biotech IPOs will increase significantly in 2026 after two barren years, but quality concerns persist as the entire ecosystem incentivizes public offerings regardless of company readiness. Historically, 60-75% of biotech IPOs underperform within two years, making careful stock selection critical for investors navigating the reopened market.
- •Obesity Drug Valuations: Obesity-focused biotech companies face pricing to perfection risk, where any clinical data falling short of beating Eli Lilly's tirzepatide triggers massive selloffs. Viking Therapeutics lost 40% market value in one day despite promising results, while Lilly dropped $60-70 billion on imperfect oral drug data, demonstrating extreme investor expectations.
- •Venture Capital Shift: Biotech's share of US venture capital dropped below 10% to approximately 7% for the first time in decades, down from 12-14% historically. Tech sector AI investments exploded the denominator while biotech stabilized at $5-6 billion quarterly. This creates overcapitalization risk for AI-native biotech companies backed by inexperienced investors making inflated valuation assumptions.
Notable Moment
Bruce Booth predicts numerous investors will face losses from overhyped AI-focused biotech investments, noting many companies receive excessive capital from tech investors lacking drug development experience who misunderstand where value inflections occur in pharmaceutical research and development timelines.
Episode Transcript
Welcome to this week's episode of The Read Out Loud, a weekly biotech podcast from STAT. I'm Alison DeAngelis. I'm Adam Feuerstein. And I'm Elaine Chen. It's Thursday, December 18. And it's our last episode of the year, folks. Woo. Yay. So to wrap up 2025, we've invited venture capitalist Bruce Booth to discuss his annual year in review report. It's basically a hefty audit of the drug industry, but we'll give you some highlights. We'll also discuss Adam's picks for best and worst CEOs in biopharma this year. First, a word from our sponsor. Hey, Read Out Loud listeners. Bob Herman here, STATS business of health care reporter and the writer behind the newsletter, HealthCare Inc. HealthCare Inc is a weekly newsletter devoted to unpacking the business and secret inner workings of The US health care industry. If you're someone who has ever received a medical bill or craves in-depth policy explainers or loves a playful meme now and again, I highly recommend you check this newsletter out. Learn more at the link in this episode's description. And now, back to our regularly scheduled programming. Thanks. Okay. So I wanna start with holiday or Christmas Hanukkah baking. Does anyone have any big baking projects? I do. Oh, Elaine, what you getting up to? So this weekend, I'm gonna make it's a pie with a chocolate cookie crust with an espresso flavored filling with a black sesame whipped cream on top. Oh my god. Elaine. Black sesame whipped cream. Speaking my language, girl. And then when Christmas around, like, when Christmas actually happens, I've been asked to make, I guess, duck has become my specialty, and I've been asked to make four ducks. Okay. So a lot of cooking. Are you doing four ducks prepared in four different ways, or are you doing four ducks prepared the same way? I I don't think I could do four different ways. Probably all the same way, but I don't think they can all fit in the oven, so I don't really know what we're gonna do. Okay. So there might be a little bit of mild chaos over at Elaine's place. There's gonna be a lot of rendered duck fat Yeah. In your I love duck fat. Place. I do. Yeah. Duck like, duck fat fried potatoes are so good. We're all coming over to Elaine's place for duck fat fries. Pardon at Elaine's house. So I am baking, in honor of this year's great British Bake Off, Jasmine being the winner, I am making a pistachio cake Cute. With, with probably with a sort of, like, cream cheese frosting. Mhmm. That sounds good. That's gonna be for Christmas dinner. Oh my gosh. You guys are making me hungry. I'm not planning on baking anything for the holidays yet. I might need to step up my game now, though. Listeners, please send recipes to me. But before the holidays, let's talk about Elaine's latest story, which takes a look at what's happening …
Get the full transcript (5,955 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 31-minute episode.
Get The Readout Loud summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from The Readout Loud
411: Capricor's data clash and a fugitive in the C-suite
Jul 30 · 36 min
Biotech Bulls & Breakthroughs
The Hidden Power of One Pivotal Trial That Changed FDA’s Game | Biotech Bulls & Breakthroughs
May 28
More from The Readout Loud
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
Jul 23 · 64 min
Masters of Scale
Why CEOs need to think more like athletes, with investor Byron Deeter
Apr 16
Books, tools, and gear mentioned in this episode
SignalCast may earn commission on purchases via these links.
newsletter
by StatNews
“SPONSORS [{'name': 'HealthCare Inc Newsletter', 'url': 'statnews.com'}]”
More from The Readout Loud
We summarize every new episode. Want them in your inbox?
411: Capricor's data clash and a fugitive in the C-suite
410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
409: Predicting biotech clinical trials & a new Alzheimer's drug controversy
408: Whistleblower takes on health insurance and FDA commissioner candidates
407: The mysterious case of Eli Lilly's obesity drug
Similar Episodes
Related episodes from other podcasts
Biotech Bulls & Breakthroughs
May 28
The Hidden Power of One Pivotal Trial That Changed FDA’s Game | Biotech Bulls & Breakthroughs
Masters of Scale
Apr 16
Why CEOs need to think more like athletes, with investor Byron Deeter
Biotech Bulls & Breakthroughs
Oct 30
Understanding Catalysts in Biotech Trading
Biotech Hangout
Aug 14
Episode 193 - August 14, 2026
The Joe Rogan Experience
Aug 11
JRE MMA Show #184 with Aljamain Sterling
Explore Related Topics
This podcast is featured in Best Health Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Health & Longevity Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into The Readout Loud.
Every Monday, we deliver AI summaries of the latest episodes from The Readout Loud and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime